Effectiveness and Safety of SIB-IMRT in Head and Neck Cancer
Author Information
Author(s): Gabriela Studer, Peter U. Huguenin, James B. Davis, Guntram Kunz, Urs M. Lütolf, Christoph Glanzmann
Primary Institution: University Hospital, Zurich, Switzerland
Hypothesis
The study aims to establish tumor response in head and neck cancer patients treated with SIB-IMRT and assess tissue tolerance following different SIB-IMRT schedules.
Conclusion
SIB-IMRT in head and neck cancer is highly effective and safe regarding tumor response and tolerance.
Supporting Evidence
- 77% of patients were alive with no disease after a mean follow-up of 18 months.
- Actuarial 2-year local, nodal, and distant disease-free survival rates were 77%, 87%, and 78%, respectively.
- Acute reactions were mild to moderate, with a low late toxicity rate of 6%.
Takeaway
This study shows that a special type of radiation therapy called SIB-IMRT works well for patients with head and neck cancer and is safe for their bodies.
Methodology
The study involved 115 head and neck cancer patients treated with various SIB-IMRT schedules and followed up for tumor response and toxicity.
Potential Biases
The study's retrospective nature may introduce bias in the analysis of outcomes.
Limitations
The study has a limited follow-up period and may not account for all long-term effects.
Participant Demographics
Median age was 60 years, with a male to female ratio of 3.4:1.
Statistical Information
P-Value
p<0.01
Confidence Interval
null
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website